Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Laura K Aguilar"'
Autor:
Francesca Barone, Paul P Tak, Sean Lawler, James A Lederer, Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, E Antonio Chiocca
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Externí odkaz:
https://doaj.org/article/06519b4a8e9e4394bfe536ab62aa59b5
Autor:
Marilin S. Koch, Mykola Zdioruk, Michal O. Nowicki, Alec M. Griffith, Estuardo Aguilar-Cordova, Laura K. Aguilar, Brian W. Guzik, Francesca Barone, Paul Peter Tak, Katharina Schregel, Michael S. Hoetker, James A. Lederer, E. Antonio Chiocca, Ghazaleh Tabatabai, Sean E. Lawler
Publikováno v:
Molecular Therapy: Oncolytics, Vol 26, Iss , Pp 275-288 (2022)
CAN-2409 is a replication-deficient adenovirus encoding herpes simplex virus (HSV) thymidine kinase (tk) currently in clinical trials for treatment of glioblastoma. The expression of tk in transduced cancer cells results in conversion of the pro-drug
Externí odkaz:
https://doaj.org/article/d1ff12c2b9db4d9895906f9830d6592e
Autor:
Mitchell G. Bryski, Jason Stadanlick, Brian W. Guzik, Patrick Woodruff, Lydia G. Frenzel-Sulyok, Edmund K. Moon, Laura K. Aguilar, Charuhas Deshpande, Estuardo Aguilar-Cordova, Steven M. Albelda, Evgeniy Eruslanov, Andrea G. Manzanera, Corey J. Langer, Jarrod D. Predina, Sunil Singhal, Marina Martinez, Andrew R. Haas, Christopher Corbett, Shaun O'Brien
Publikováno v:
Molecular Therapy
Gene-mediated cytotoxic immunotherapy (GMCI) is an immuno-oncology approach involving local delivery of a replication-deficient adenovirus expressing herpes simplex thymidine kinase (AdV-tk) followed by anti-herpetic prodrug activation that promotes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04a9e6c798bf28eac1e5e6c327b25bfd
http://europepmc.org/articles/PMC7854297
http://europepmc.org/articles/PMC7854297
Autor:
Marilin S Koch, Mykola Zdioruk, Michal O Nowicki, Alec M Griffith, Estuardo Aguilar, Laura K Aguilar, Brian W Guzik, Francesca Barone, Paul P Tak, Ghazaleh Tabatabai, James A Lederer, E Antonio Chiocca, Sean Lawler
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 1 (2022)
BackgroundIntratumoral viral oncolytic immunotherapy is a promising new approach for the treatment of a variety of solid cancers. CAN-2409 is a replication-deficient adenovirus that delivers herpes simplex virus thymidine kinase to cancer cells, resu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82b8be09b80beec58beda1af9d511f57
https://pubmed.ncbi.nlm.nih.gov/35017150
https://pubmed.ncbi.nlm.nih.gov/35017150
Autor:
E Antonio Chiocca, Hiroshi Nakashima, Xiaokui Mo, Isaac Solomon, Alexander Ling, Jared Woods, Joshua Bernstock, Genaro Villa, Raziye Piranlioglu, Ana Montalvo Landivar, Nafisa Masud, Daniel Triggs, James Grant, Patrick Y Wen, Eudocia Lee, Lakshmi Nayak, Ugonma Chukwueke, Tracy Batchelor, David Krisky, Estuardo Aguilar-Cordova, Laura K Aguilar, Soledad Fernandez, Christopher Matheny, Andrea Manzanera, Francesca Barone, Paul Peter Tak, Keith Ligon, David A Reardon
Publikováno v:
Neuro-Oncology. 24:vii61-vii61
BACKGROUND CAN-3110 (rQNestin34.5v2) is an HSV-1 oncolytic viral immunotherapy with one copy of the inflammatory ICP34.5 gene under transcriptional control of the Nestin glioma-specific promoter. We completed a phase 1 sequential dose-escalation tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::19461b0ab541fea08c319be4c93a0c22
https://doi.org/10.1093/neuonc/noac209.241
https://doi.org/10.1093/neuonc/noac209.241
Autor:
Liliana Goumnerova, Stewart Goldman, Rishi Lulla, Estuardo Aguilar-Cordova, Susan N. Chi, Peter E. Manley, Andrea G. Manzanera, Mark W. Kieran, Tadanori Tomita, Karen J. Marcus, Laura K. Aguilar, Arthur J DiPatri
Publikováno v:
Neuro-Oncology. 21:537-546
Background Gene-mediated cytotoxic immunotherapy (GMCI) is a tumor-specific immune stimulatory strategy implemented through local delivery of aglatimagene besadenovec (AdV-tk) followed by anti-herpetic prodrug. GMCI induces T-cell dependent tumor imm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f0eb64f64c50a164d5c836477183038
https://doi.org/10.1093/neuonc/noy202
https://doi.org/10.1093/neuonc/noy202
Autor:
Charu Aggarwal, Andrew Haas, Sarah W. Gordon, Ranee Mehra, Peter M Lee, Christine M. Bestvina, Fabien Maldonado, Vamsidhar Velcheti, Roy S. Herbst, Susan D. Bell, Rachael Gillmor, Andrea Manzanera, Christopher Jon Matheny, Estuardo Aguilar-Cordova, Laura K. Aguilar, Francesca Barone, Paul Peter Tak, Daniel Sterman
Publikováno v:
Journal of Clinical Oncology. 40:9037-9037
9037 Background: Immune checkpoint inhibitors (ICI) are standard of care for advanced NSCLC. Even among patients with initial response, a majority ultimately progress, and rational combination approaches are needed to improve outcomes. CAN-2409 is a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::efca07d2c147ddd132e5baddc888bf8a
https://doi.org/10.1200/jco.2022.40.16_suppl.9037
https://doi.org/10.1200/jco.2022.40.16_suppl.9037
Autor:
Lawrence A. Shirley, Laura K. Aguilar, Estuardo Aguilar-Cordova, Mark Bloomston, Jon P. Walker
Publikováno v:
Gastroenterology Research and Practice, Vol 2013 (2013)
Pancreatic adenocarcinoma is an aggressive disease that has poor outcomes despite maximal traditional therapies. Thus, treatment of this cancer demands innovative strategies to be used in addition to standing therapies in order to provide new avenues
Externí odkaz:
https://doaj.org/article/0123f03e49ba4e228f2f224ed1c19179
Autor:
Laura K. Aguilar, Ghazaleh Tabatabai, Marilin Koch, Brian W. Guzik, Michał Nowicki, Estuardo Aguilar-Cordova, Sean E. Lawler, E. Antonio Chiocca, Mikolay Zdioruk
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background Gene-mediated cytotoxic immunotherapy (GMCI) is a local tumor immunotherapy that uses aglatimagene besadenovec (a non-replicating serotype 5 adenovirus, expressing HSV1 thymidine kinase) with the prodrug ganciclovir to induce DNA double st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df794863829b5af32bedde886ad58c49
https://doi.org/10.1136/jitc-2020-sitc2020.0468
https://doi.org/10.1136/jitc-2020-sitc2020.0468
Autor:
Estuardo Aguilar-Cordova, Serena Desideri, Pierpaolo Peruzzi, Patrick Y. Wen, Wenya Linda Bi, Frank S. Lieberman, Ian Lee, James Snyder, Steven Brem, Paul Peter Tak, Sean E. Lawler, Susan Bell, Stephen J Bagley, Nirav J. Patel, Andrea G. Manzanera, E. Antonio Chiocca, Francesca Barone, Nduka Amankulor, Lenika Lopez, L. Burt Nabors, Megan Mantica, Neeraja Danda, Brian W. Guzik, Stephen B. Tatter, Stuart A. Grossman, Tobias Walbert, Laura K. Aguilar, Roy E. Strowd, Lixian Jin, Arati Desai, William Timmer, Xiaobu Ye, David A. Reardon
Publikováno v:
Neuro-Oncology. 23:vi52-vi52
BACKGROUND CAN-2409 is a replication-deficient adenovirus that delivers HSV thymidine kinase to cancer cells, resulting in local conversion of orally administered valacyclovir into a toxic metabolite. Previously, a phase 1b/2 clinical trial of CAN-24
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::878ef996c3d5f0cfe21fd7134a1d39b1
https://doi.org/10.1093/neuonc/noab196.205
https://doi.org/10.1093/neuonc/noab196.205